title: Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.
abstract: OBJECTIVE
  Inhaled corticosteroids are used to treat COPD and asthma. An association between sequence variants in the corticotrophin-releasing hormone receptor 1 (CRHR1) gene and improved lung function in asthmatics treated with inhaled corticosteroids was reported recently. This study investigated the association between the change in lung function in response to inhaled corticosteroids and single-nucleotide CRHR1 polymorphisms in patients with COPD.
  
  
  METHODS
  COPD patients (n = 87) with a positive smoking history were recruited from the pulmonary clinics of 11 hospitals in Korea. Patients were treated with fluticasone propionate and salmeterol for 12 weeks and lung function was measured at baseline and after the 12-week treatment. Eighty-four of the 87 subjects were successfully genotyped.
  
  
  RESULTS
  Seventy-one patients with the wild-type GG genotype and 13 patients with the heterozygous GT genotype in rs242 941 were evaluated. After 12-week treatment, the change in FEV(1) was significantly higher in patients with wild-type GG genotype (6.0 +/- 0.8% of predicted FEV(1)) than in GT heterozygotes (-0.8 +/- 1.8, P = 0.003).
  
  
  CONCLUSIONS
  Improved FEV(1) following inhaled corticosteroid and a long-acting beta2-agonist was associated with CRHR1 genetic polymorphism in patients with COPD.
authors.affiliation: Department of Internal Medicine, College of Medicine, Kangwon National University, Chuncheon, Korea.
authors.forename: Woo J
authors.initials: WJ
authors.lastname: Kim
authors.forename: Seung S
authors.initials: SS
authors.lastname: Sheen
authors.forename: Tae-Hyung
authors.initials: TH
authors.lastname: Kim
authors.forename: Jin W
authors.initials: JW
authors.lastname: Huh
authors.forename: Ji-Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Eun-Kyung
authors.initials: EK
authors.lastname: Kim
authors.forename: Jin H
authors.initials: JH
authors.lastname: Lee
authors.forename: Sang-Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Sangyeub
authors.initials: S
authors.lastname: Lee
authors.forename: Seong Y
authors.initials: SY
authors.lastname: Lim
authors.forename: Tae R
authors.initials: TR
authors.lastname: Shin
authors.forename: Ho I
authors.initials: HI
authors.lastname: Yoon
authors.forename: Yeon-Mok
authors.initials: YM
authors.lastname: Oh
authors.forename: Sang D
authors.initials: SD
authors.lastname: Lee
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D018019:Receptors, Corticotropin-Releasing Hormone / Q000235:genetics*; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome; D000099052:CRF Receptor, Type 1
chemical_list: D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D001993:Bronchodilator Agents; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol